Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35100 Padova, Italy.
Department of Medicine, University of Padova, 35100 Padova, Italy.
Mar Drugs. 2020 Jan 17;18(1):62. doi: 10.3390/md18010062.
The Asian coastal communities have used the brown seaweeds and since ancient times. Recently, some in vitro and in vivo studies have demonstrated their abilities in reducing risk factors for metabolic syndrome. Here, we analyzed the protective effect of a phytocomplex extracted from these seaweeds on the deposition of fat in the liver after the administration of a high-fat diet (HFD) to rats for five weeks. The administration of and led to significant reductions in microvescicular steatosis and plasma biochemical and lipid parameters, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and conjugated bilirubin, and triglycerides. Furthermore, the postprandial glycemic peak was delayed and significantly reduced ( < 0.01) by the algal extract administration. In conclusion, this extract is effective in reducing microvescicular steatosis and improving glycemic control, thereby lowering the risk of nonalcoholic fatty liver disease, obesity, and diabetes, diseases related to the consumption of fat and sugar-enriched diets.
亚洲沿海社区自古就一直使用褐藻。最近,一些体外和体内研究表明它们具有降低代谢综合征风险因素的能力。在这里,我们分析了从这些海藻中提取的植物复合物对大鼠高脂饮食(HFD)五周后肝脏脂肪沉积的保护作用。 和 的给药导致微泡性脂肪变性和血浆生化和脂质参数(如丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、总胆红素和结合胆红素以及甘油三酯)的显著降低。此外,餐后血糖峰值被海藻提取物给药延迟并显著降低( < 0.01)。总之,这种提取物可有效减少微泡性脂肪变性并改善血糖控制,从而降低非酒精性脂肪肝、肥胖症和糖尿病的风险,这些疾病与食用富含脂肪和糖的饮食有关。